An assessment of adverse effects of antiretroviral therapy on the development of HIV positive children by observation of dental mineralization chronology

被引:12
作者
Trigueiro, M. [1 ]
Tedeschi-Oliveira, S. V. [1 ]
Melani, R. F. H. [1 ]
Ortega, K. L. [2 ]
机构
[1] Univ Sao Paulo, Dept Social Dent, Fac Odontol, BR-05508000 Sao Paulo, Brazil
[2] Univ Sao Paulo, Dept Stomathol, Fac Odontol, BR-05508000 Sao Paulo, Brazil
关键词
dental chronology; HAART; HIV; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED CHILDREN; HIV-1-INFECTED CHILDREN; PEDIATRIC AIDS; GROWTH; AGE; EVENTS; COMPLICATIONS; ADOLESCENTS; PREVALENCE;
D O I
10.1111/j.1600-0714.2009.00856.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: The difference between dental age (DA) and chronological age (CA) indicates an advance or delay in comparison with the normal standard. Considering that DA has a very close correlation with CA in a developing child, this study aimed to investigate the relationship between the effects of antiretroviral therapy on the development of HIV positive children, by observing the timing of dental mineralization. Methods: A retrospective examination was made of the medical records and dental panoramic radiographs of 50 HIV-positive pediatric patients, aged 37-168 months of age. Through these radiographs, their DA was estimated and compared with their CA. Results: The mean DA was significantly lower than the mean CA in the entire studied sample (P < 0.01). There was a statistical difference between children who received antiretroviral drugs and those who used no drugs (P = 0.02), i.e. the non-treated individuals presented practically no difference between CA and DA, while the treated patients showed a difference of 10.67 months. Conclusion: We conclude that the DA of HIV infected children was delayed when compared to the CA, and there was a positive association between the use of antiretroviral therapy and a delay in the chronology of dental mineralization in the sample.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 45 条
  • [1] Amorosa V, 2006, CLIN INFECT DIS, V42, P108, DOI 10.1086/498511
  • [2] Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors
    Boccara, Franck
    [J]. AIDS, 2008, 22 : S19 - S26
  • [3] Brück S, 2008, EUR J MED RES, V13, P343
  • [4] Growth parameters in HIV-vertically-infected adolescents on antiretroviral therapy in Rio de Janeiro, Brazil
    Buonora, Sibelle
    Nogueira, Susie
    Pone, Marcus Vinicius
    Aloe, Marisa
    Oliveira, Ricardo Hugo
    Hofer, Cristina
    [J]. ANNALS OF TROPICAL PAEDIATRICS, 2008, 28 (01): : 59 - 64
  • [5] Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
    Cameron, DW
    Heath-Chiozzi, M
    Danner, S
    Cohen, C
    Kravcik, S
    Maurath, C
    Sun, E
    Henry, D
    Rode, R
    Potthoff, A
    Leonard, J
    [J]. LANCET, 1998, 351 (9102) : 543 - 549
  • [6] Insulin-like growth factor-1 and lean body mass in HIV-infected children
    Chantry, Caroline J.
    Hughes, Michael D.
    Alvero, Carmelita
    Cervia, Joseph S.
    Hodge, Janice
    Borum, Peggy
    Moye, Jack, Jr.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 48 (04) : 437 - 443
  • [7] Costa LRRS, 1998, J DENT CHILD, V65, P186
  • [8] Davidson LE, 2001, COMMUNITY DENT HLTH, V18, P27
  • [9] Del Toro Agnes, 1996, Pediatric Dentistry, V18, P114
  • [10] Eley B, 2008, EXPERT OPIN DRUG MET, V4, P37, DOI [10.1517/17425255.4.1.37, 10.1517/17425255.4.1.37 ]